By not defining BP target maintenance, current guidelines unintentionally lead to "undershoot"
When treating high BP, it is a statistical inevitability that on average future BP will be above target if treatment intensification is stopped the first time a BP measure is below target. This phenomenon occurs because of inherent BP variability, by time of day, day of week, season, and so on. The probability any one measure will be close to true long-term average BP is very small. If one chooses the first measure below a threshold, then the average of future measures will likely be above that threshold. This is for the same reason that multiple measures are required to confirm a diagnosis of hypertension; a particularly high BP will tend to be followed by less high BP levels.
Multiple measures are always specified for diagnosis of hypertension but never at present for BP control. No guidelines yet specify how many measures over what time define meeting a BP target. None warn that the first below target measure may well be 'too good to be true' and so most patients will require further treatment intensification. Common clinical practise is therefore to stop treatment intensification after the first measure below a BP target. Once a regimen is established, treatment inertia becomes a powerful force: treatment regimens are usually not altered when high BP is measured. 3 One reason is the mismatch between perceived and actual control. 4 Cognitive biases operate extensively in medicine, 5, 6 including confirmation bias-a tendency to give more attention and belief to desirable measures and to discount undesirable information. In practical terms, "your BP has been controlled, the high measure today was probably just an off day".
A valid definition of a BP target should include both a time dimension (we suggest at least a year, given the large seasonal changes in BP levels 7, 8 ) and a minimum proportion of measures that must be within target (we suggest at least half of all measures, with BP measures taken at least quarterly). One could also consider defining 'initial control' and 'sustained control' as most measures being below target for a month and a year, respectively. An annual BP profile should be regarded as a minimum requirement to assess the lifelong issue of high BP.
Current guidelines continue to recommend inefficient strategies for reaching BP targets
Randomized trials show the extra BP reduction from adding an agent is many times more than the 1-2 mmHg extra BP reduction from doubling the dose.
9,10 And for some drug classes, doubling the dose markedly increases side effects. In a systematic review of dual vs. triple BP lowering drugs, adding a third drug was better than doubling the dose of an existing drug, for both efficacy and tolerability (A. Salam, personal communication) . However, for patients uncontrolled on monotherapy, some guidelines continue to recommend dose titration or switching alongside adding a second agent. For patients uncontrolled on two drugs, almost all current guidelines recommend gradually increasing the dose of one then the other agent, before a third is used. The historical regulatory practise of requiring all possible dose permutations in fixed dose combinations enables this practise, although more recently the FDA has stated 'Over the last decade, the Agency has actively discouraged antihypertensive monotherapy and combination doses with effects that were very close together, considering them a nuisance to physicians seeking to get patients to goal'.
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Generally the visit-to-visit intra-individual BP standard deviation is around 15/10mmHg (and it takes many repeat measures to be meaningfully reduced
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) and so the signal-to-noise ratio means treatment effect from dose doubling will be swamped by BP variation.
Again, this is fertile ground for cognitive biases to operate, with multiple opportunities to misconstrue visit-to-visit BP differences as evidence of treatment efficacy or lack of change as evidence of lack of efficacy. This continued reliance on slow, measurement-intensive, dose titration strategies that are not evidence-based imposes a considerable burden on patients and on payers. Most importantly it often results in under-treatment. 'Start low, go slow' usually becomes 'start low, stop'. Perhaps the most potent reason for controversy in the literature around BP targets at the moment is the amount of attention paid to non-randomized analyses. This problem could increase over time as capacity for big data analyses increases exponentially, whereas few major new trials are ongoing. The continued reporting of nonrandomized analyses and BP J-curves is surprising, given the long history of the dangers of non-randomized evidence in the assessment of efficacy and safety of cardiovascular treatments. For example, in the 1990s, there were numerous high-profile publications about associations between low cholesterol and adverse outcomes, suggesting that statins could be dangerous. 13,14 These J-curves had some biological plausibility, were seen repeatedly in large-scale data sets and remained after extensive adjustments. When large-scale trials showed no harm from reducing cholesterol to low levels, these publications stopped and the field moved on. The discrepancy was used as a teaching example of how reverse causality and residual confounding can mislead in non-randomized analyses: as a prime example of why trials are needed. However, non-randomized analyses of BP associations and inferences about treatment efficacy and safety continue to proliferate, despite many trials directly refuting increased risk with intensive BP lowering.
2,15,16 One possible reason is a biological plausibility argument, relating to necessary perfusion pressure, especially for diastolic pressure in patients with compromised coronary circulation. The argument goes that since no blood pressure would be fatal, there must be some threshold-which is true, but it tells us nothing about where that threshold is. Consider a technology that extracted all cholesterol or temperature from the body-it would be fatal also, but this would tell us nothing where the threshold is. We need trials for this determination. And trials show no increase, either acutely or long term, even with beta-blockers that substantially reduce diastolic pressures in patients with low BP and severely comprised coronary circulation (recent acute myocardial infarction, heart failure) or in trials of highrisk treated to very low levels.
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Even when randomized evidence is reviewed, there has been a tendency to focus on a subset of trials, such as those most recently published. The dangers of this approach are well recognized. 18, 19 We suggest the field has suffered from 'pixellation'-evidence viewed piecemeal, without assessing the big picture. Over 80 trials have randomized over 300 000 patients, 20 so it is surprisingly easy to be misled by subsets of trials and/or subgroups within trials. The randomized trial evidence for benefits of BP lowering below 140 mmHg was clear over a decade ago 21 but still reviews tend to include only small subsets of randomised trials. Whether or not to actually pool data from different trials is an issue of judgement that has been ongoing since meta-analyses and systematic reviews began. But few would disagree with the need to consider evidence from similar interventions alongside each other. One would never ignore a side effect of a drug found in one trial population if one was interested in treating a different population. We suggest the greatest danger lies in not taking into account largescale randomized evidence on BP-lowering drugs just because of differences in patient population or presumed mechanism. Perhaps the starkest example was the JNC8 guidelines that considered only a small proportion of all BP-lowering trials and explicitly excluded all others from consideration.
Defining better BP goals is seeking a better answer to a worse question
Ultimately a clinical decision strategy that is based solely, or mainly, on BP will be non-optimal. There is a strong evidence-based rationale for treating principally on absolute cardiovascular risk and capacity to benefit. [23] [24] [25] [26] We suggest a patient is best regarded as not being at BP target if there is residual cardiovascular risk that could be averted by BP lowering, and the absolute benefits are likely to comfortably exceed the risks. This approach appropriately leads to different clinical decisions in patients with identical BPs. Consider three patients with BP in the 130-90 mmHg range, ordered in terms of their risk of cardiovascular disease; first a 30-year-old woman with no other cardiovascular risk factors; second a 50-year-old man with 5-year cardiovascular risk of 20% as a consequence of age, sex, and several modestly raised cardiovascular risk factors; third a 70-year-old woman with co-morbid cancer and chronic obstructive pulmonary disease (COPD) and a life expectancy of under 24 months. Initiating pharmacological treatment, we would suggest, may not provide worthwhile net benefits for the first or third patient, but would be of considerable net benefit for the second. Two other advantages of a 'capacity-to-benefit' absolute risk-based approach are apparent. First, in contrast to BP levels, one can accurately assess absolute cardiovascular risk in one clinic visit. Because risk estimation involves multiple largely uncorrelated measures, there will be little visit-to-visit variability. Second, a treatment goal of 'benefits exceeding harms' is a clinically universal one and is not expected to change in coming years. This is in contrast to BP goals, with a huge number of different goals recommended by different guidelines for different patient groups over the years and as can be seen in Table 1 , very little consistency across trials in the definition of targets.
Conclusion
Underuse of combination therapy, treatment inertia and undetected non-adherence 27,28 are well-recognized reasons for not meeting BP targets. Here, we have outlined two other less wellrecognized factors: a failure to warn clinicians that further treatment intensification is likely to be needed after the first measure below a BP goal and continued guideline recommendations to titrate existing drugs, despite randomized evidence that adding a BP drug is typically far preferable. The unpalatable truth for patients and physicians alike is that very few people have optimal BP-we live in societies in which the dietary environment and physical activity levels almost inevitably lead to a steady rise in BP with age, which is not seen in pre-modern societies. 29 In a world in which non-optimal BP is the norm, the main clinical question is what are the marginal benefits of treatments-are the absolute benefits worth the cost and side effects? We have a strong tendency to unconsciously replace difficult-but-optimal questions for easy-but-imperfect ones.
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'Is this patient above goal BP?' is a simple question but an imperfect one. A much better question is 'Would this patient meaningfully benefit from BP lowering?'
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The future of . . . series
Status and future of genomics in blood pressure
Will a genetic link to the risk of hypertension be found?
Hypertension genomics have come a long way from the initial beginnings of the 2007 Wellcome Trust Case Control Consortium genome-wide association study (GWAS), 1 which failed to identify genetic associations due to relatively small sample sizes. Now, 10 years on, GWASs have grown by several orders of magnitude, with study sizes typically surpassing a quarter of a million participants, identifying over 200 novel loci for blood pressure in white Europeans and extending to East Asians and African ancestry. Newer GWAS methodologies are taking this further. By assessing rare variants, the total known blood pressure-associated variants have increased, in particular, rare missense variants demonstrating larger effects (>1.5 mm Hg/allele).
2 Custom genotyping microarrays designed to facilitate targeted, cost-effective follow-up of nominal associations for metabolic and cardiovascular traits have also identified novel blood pressure genetic loci, together with fine-mapping of previously known signals. Recently, studies have begun to evaluate the trajectory in blood pressure changes over years, 4 using electronic health records, 5 or pooled DNA, 6 with varying success. In addition to GWASs, there are an increasing number of multi-omics studies in blood pressure, including pharmacogenomics, epigenomics, and transcriptomics. The studies described here are not exhaustive and aim to provide an overview of current knowledge, where the future may lie, and what challenges that may need to be overcome.
A key goal of GWASs was to identify potential new therapeutic targets. The list of hitherto-discovered genetic loci shows some familiarity-ACE (angiotensin converting enzyme), ADRB1 (beta-1 adrenergic receptor), AGT (angiotensinogen), CACNB2 (voltage-gated calcium channel subunit), NOS3 (endothelial nitric oxide synthase), NPR3 (atrial natriuretic peptide receptor C), and PDE5A (phosphodiesterase 5A)-all to varying degrees of gene products within current pharmacological target pathways. Furthermore, a genetic locus at MME (membrane metalloendopeptidase) strongly supports the ongoing development of neprilysin inhibitors such as sacubitril as a therapeutic option for hypertension. However, the identification of new candidate genes or causative variants has proven to be complex, primarily due to the nature of genetic recombination and the usage of single nucleotide polymorphisms (SNPs) spaced throughout the genome. This means that novel loci may span numerous genes (exemplified by rs116556354 in Figure 1 ). Alternatively, they may encompass a purely intergenic genomic region or have a large number of SNPs being co-inherited (SNPs in high-linkage disequilibrium can sometimes reach >100). To further complicate matters, the genetic effects may be cell-type
